NVS
Price
$138.88
Change
-$0.25 (-0.18%)
Updated
Dec 24 closing price
Capitalization
268.24B
41 days until earnings call
Intraday BUY SELL Signals
RHHVF
Price
$415.31
Change
-$3.97 (-0.95%)
Updated
Dec 24 closing price
Capitalization
334.29B
35 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NVS vs RHHVF

Header iconNVS vs RHHVF Comparison
Open Charts NVS vs RHHVFBanner chart's image
Novartis AG
Price$138.88
Change-$0.25 (-0.18%)
Volume$646.98K
Capitalization268.24B
Roche Holding
Price$415.31
Change-$3.97 (-0.95%)
Volume$777
Capitalization334.29B
NVS vs RHHVF Comparison Chart in %
NVS
Daily Signal:
Gain/Loss:
RHHVF
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NVS vs. RHHVF commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a StrongBuy and RHHVF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (NVS: $138.88 vs. RHHVF: $415.30)
Brand notoriety: NVS and RHHVF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: NVS: 37% vs. RHHVF: 5%
Market capitalization -- NVS: $268.24B vs. RHHVF: $334.29B
NVS [@Pharmaceuticals: Major] is valued at $268.24B. RHHVF’s [@Pharmaceuticals: Major] market capitalization is $334.29B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $963.92B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $104.36B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVS’s FA Score shows that 3 FA rating(s) are green whileRHHVF’s FA Score has 2 green FA rating(s).

  • NVS’s FA Score: 3 green, 2 red.
  • RHHVF’s FA Score: 2 green, 3 red.
According to our system of comparison, NVS is a better buy in the long-term than RHHVF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVS’s TA Score shows that 5 TA indicator(s) are bullish while RHHVF’s TA Score has 4 bullish TA indicator(s).

  • NVS’s TA Score: 5 bullish, 4 bearish.
  • RHHVF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, NVS is a better buy in the short-term than RHHVF.

Price Growth

NVS (@Pharmaceuticals: Major) experienced а +2.85% price change this week, while RHHVF (@Pharmaceuticals: Major) price change was +5.80% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.05%. For the same industry, the average monthly price growth was +2.64%, and the average quarterly price growth was +14.79%.

Reported Earning Dates

NVS is expected to report earnings on Feb 04, 2026.

RHHVF is expected to report earnings on Jan 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (+2.05% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RHHVF($334B) has a higher market cap than NVS($268B). RHHVF has higher P/E ratio than NVS: RHHVF (27.86) vs NVS (19.00). RHHVF (48.323) and NVS (47.857) have similar YTD gains . NVS has higher annual earnings (EBITDA): 22.9B vs. RHHVF (18B). RHHVF has more cash in the bank: 12B vs. NVS (9.75B). NVS (32B) and RHHVF (33B) have identical debt. RHHVF has higher revenues than NVS: RHHVF (63.5B) vs NVS (56.4B).
NVSRHHVFNVS / RHHVF
Capitalization268B334B80%
EBITDA22.9B18B127%
Gain YTD47.85748.32399%
P/E Ratio19.0027.8668%
Revenue56.4B63.5B89%
Total Cash9.75B12B81%
Total Debt32B33B97%
FUNDAMENTALS RATINGS
NVS vs RHHVF: Fundamental Ratings
NVS
RHHVF
OUTLOOK RATING
1..100
2150
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
1170
SMR RATING
1..100
2899
PRICE GROWTH RATING
1..100
4341
P/E GROWTH RATING
1..100
3615
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVS's Valuation (15) in the Pharmaceuticals Major industry is in the same range as RHHVF (16) in the null industry. This means that NVS’s stock grew similarly to RHHVF’s over the last 12 months.

NVS's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for RHHVF (70) in the null industry. This means that NVS’s stock grew somewhat faster than RHHVF’s over the last 12 months.

NVS's SMR Rating (28) in the Pharmaceuticals Major industry is significantly better than the same rating for RHHVF (99) in the null industry. This means that NVS’s stock grew significantly faster than RHHVF’s over the last 12 months.

RHHVF's Price Growth Rating (41) in the null industry is in the same range as NVS (43) in the Pharmaceuticals Major industry. This means that RHHVF’s stock grew similarly to NVS’s over the last 12 months.

RHHVF's P/E Growth Rating (15) in the null industry is in the same range as NVS (36) in the Pharmaceuticals Major industry. This means that RHHVF’s stock grew similarly to NVS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVSRHHVF
RSI
ODDS (%)
Bearish Trend 2 days ago
42%
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
58%
Momentum
ODDS (%)
Bullish Trend 2 days ago
52%
Bullish Trend 2 days ago
59%
MACD
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
63%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
49%
Bullish Trend 2 days ago
53%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
43%
Bullish Trend 2 days ago
55%
Advances
ODDS (%)
Bullish Trend 3 days ago
49%
Bullish Trend 7 days ago
55%
Declines
ODDS (%)
Bearish Trend 18 days ago
44%
Bearish Trend 9 days ago
57%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
35%
Bearish Trend 2 days ago
56%
Aroon
ODDS (%)
Bullish Trend 2 days ago
41%
Bullish Trend 2 days ago
48%
View a ticker or compare two or three
Interact to see
Advertisement
NVS
Daily Signal:
Gain/Loss:
RHHVF
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
OVB20.670.11
+0.55%
Overlay Shares Core Bond ETF
QUVU27.680.15
+0.54%
Hartford Quality Value ETF
MEGI13.780.05
+0.36%
NYLI CBRE Global Infrastructure Megatrends Term Fund
VONG123.620.31
+0.25%
Vanguard Russell 1000 Growth ETF
SFTY28.500.07
+0.25%
Horizon Managed Risk ETF

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
-0.18%
GSK - NVS
67%
Closely correlated
+0.23%
AZN - NVS
62%
Loosely correlated
+0.34%
PFE - NVS
59%
Loosely correlated
+0.60%
AMGN - NVS
56%
Loosely correlated
+0.75%
JNJ - NVS
52%
Loosely correlated
+0.97%
More

RHHVF and

Correlation & Price change

A.I.dvisor indicates that over the last year, RHHVF has been loosely correlated with RHHBY. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RHHVF jumps, then RHHBY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RHHVF
1D Price
Change %
RHHVF100%
-0.94%
RHHBY - RHHVF
65%
Loosely correlated
-0.10%
JNJ - RHHVF
31%
Poorly correlated
+0.97%
NVS - RHHVF
27%
Poorly correlated
-0.18%
AZN - RHHVF
26%
Poorly correlated
+0.34%
RHHBF - RHHVF
25%
Poorly correlated
N/A
More